# Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

> **NCT06494150** · PHASE2 · RECRUITING · sponsor: **University of Oklahoma** · enrollment: 37 (estimated)

## Conditions studied

- Low Grade Ovarian Serous Adenocarcinoma

## Interventions

- **DRUG:** nab-Sirolimus
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT06494150
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2027-08
- **Final completion:** 2029-09
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494150, "Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06494150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*